Skip to main content
Download PDF

RETRACTED ARTICLE: Melatonin levels and embryo quality in IVF patients with diminished ovarian reserve: a comparative study

Reproductive Biology and Endocrinology volume 22, Article number: 127 (2024) Cite this article

This article was retracted on 17 March 2025

This article has been updated

Abstract

Background

Melatonin, a hormone found in various bodily fluids and cells, is known for its potent antioxidative, anti-apoptotic, and endocrine regulatory properties. This study aimed to analyze melatonin levels in patients with diminished ovarian reserve (DOR) and its impact on embryo quality.

Methods

We enrolled 85 women who were undergoing in vitro fertilization or intracytoplasmic sperm injection procedures, including normal ovarian reserve (NOR, n = 27), pathological DOR (DOR-Path, n = 25), and physiological DOR (DOR-Phy, n = 33). Melatonin levels in patient serum and follicular fluid were assessed using ELISA, and correlations between melatonin levels and indicators of embryo quality were examined.

Results

Our findings indicate that melatonin levels in the follicular fluid and basal serum of the DOR-Path and DOR-Phy groups were lower compared to the NOR group (P < 0.05). However, no significant differences in melatonin levels were found between the DOR-Path and DOR-Phy groups (P > 0.05). Additionally, the concentration of melatonin in the follicular fluid of the NOR group was significantly higher than in their serum (P < 0.001). Lastly, a significant correlation was discovered between melatonin levels in serum and follicular fluid and parameters of ovarian reserve and embryonic development (P < 0.05).

Conclusions

Melatonin levels in DOR patients may impact embryo quality, offering insights into potential DOR pathogenesis and opportunities to enhance treatment outcomes in these patients.

Introduction

The escalating rates of reproductive infertility in both sexes have intensified as a consequential global public health issue [1, 2]. Epidemiological studies report a substantial 50% surge in infertility prevalence over the past six decades [3]. Remarkably, ap-proximately 35% of cases involving couples unable to conceive are linked to ovarian failure [4]. While ovarian function naturally wanes around the age of 40, recent clinical data underscore a rising trend in diminished ovarian reserve occurring at earlier stages [5]. This divergence from the expected decline in ovarian function within the same age group categorizes ovarian aging into two distinct types: physiological diminished ovarian reserve correlated with advanced age (DOR-Phy) and pathological diminished ovarian reserve unrelated to age (DOR-Path) [6, 7].

Contemporary research throughout this year has elucidated melatonin’s pivotal role in preserving the physiological and molecular facets of both normal and aging ovaries [8]. Melatonin, chemically known as N-acetyl-5-methoxytryptamine, is an indoleamine syn-thesized by diverse cells and rhythmically released by the pineal gland [9]. Its secretion follows a distinct circadian rhythm, predominantly occurring at night and regulated by the suprachiasmatic nucleus of the hypothalamus, underscoring its integral role in the circadian system [10]. Engaging in multifaceted physiological functions, melatonin acts as a potent antioxidant, manifesting protective effects against oxidative stress and in-flammation [11, 12]. Additionally, it operates as an immune-active agent and mitochon-drial modulator, contributing to immune modulation, cardiovascular regulation, neuro-protection, and more [13].

Melatonin’s presence within ovarian follicular fluid and oocytes acts as a shield against oxidative damage and confers supplementary benefits by enhancing oocyte maturation, fertilization, and embryo development [4]. Demonstrating the capability to impede ovarian aging, melatonin regulates ovarian biological rhythms, fosters follicle formation, and augments oocyte quality and fertilization rates [14]. Furthermore, melatonin significantly facilitates oocyte maturation and embryo development by regulating the hypothalamic-pituitary axis and acting directly as an antioxidant. In clinical treatments for infertile women, melatonin has shown potential in reducing oxidative damage and improving fertilization rates [15]. Research has indicated that the combined use of melatonin and metformin can effectively restore infertility symptoms in polycystic ovary syndrome mice, including morphological changes in the ovaries and uterus, as well as improvements in hormone levels [16]. Additionally, studies by Feng et al. using animal models have found that melatonin can effectively prevent ovarian insufficiency induced by chemotherapy, thereby protecting ovarian reserve and fertility [17].

This evidence unequivocally underscores melatonin’s pivotal role in the context of ovarian aging. Understanding that follicular fluid, as the microenvironment for oocytes, profoundly influences oocyte development and developmental potential [18], recent re-search has proposed melatonin levels in follicular fluid as markers for in vitro fertilization (IVF) outcomes and predictors of ovarian reserve [19]. Nonetheless, the elucidation of melatonin levels in the follicular fluid and serum of patients with various types of diminished ovarian reserve remains unresolved. Therefore, this study endeavors to scrutinize melatonin levels in patients with DOR-Path, DOR-Phy, and NOR, aiming to delineate their impact on oocyte parameters and embryo quality. The resultant findings will significantly contribute to a nuanced comprehension of the role of melatonin in premature ovarian failure.

Materials and methods

Study population

This investigation enrolled 85 female volunteers who underwent IVF/ICSI treatment at the Reproductive Center of Luohu District People’s Hospital in Shenzhen between September 2022 and August 2023.

The recruited volunteers were divided into three groups based on their ovarian re-serve and age: (1) patients with normal ovarian reserve (NOR group, denoted as the control group). Inclusion criteria were as follows: age ≤ 35, anti-Müllerian hormone (AMH) ≥ 1.1 ng/ml, antral follicle count (AFC) > 10, and requiring assisted reproductive treatment due to male factors. (2) Pathological diminished ovarian reserve (DOR-Path group). Inclusion criteria were: age ≤ 35, AMH < 1.1 ng/ml, and AFC < 6. (3) Physiologic diminished ovarian reserve (DOR-Phy group). Inclusion criteria were: age > 40, AMH < 1.1 ng/ml, and AFC < 6 [20]. Exclusion criteria for all recruited volunteers included autoimmune diseases, chromosomal abnormalities in both partners, acute infectious diseases, reproductive system tumors, ovarian endometriomas, adenomyosis, hyperprolactinemia, pelvic inflammatory disease, and related disorders.

IVF protocols

The protocol for ovarian stimulation (OS) was determined individually according to standard practice and the patient’s characteristics, including age, BMI, basal folli-cle-stimulating hormone (FSH), and antral follicle count (AFC), anti-Müllerian hormone (AMH), basal luteinizing hormone (LH), and basal estradiol (E2). Most patients were treated with a long Gonadotropin-releasing hormone (GnRH) agonist or a GnRH an-tagonist protocol [21]. For women with diminished ovarian reserves, the mild ovulation protocol [22] or luteal phase ovarian [23] stimulation was attempted. In these protocols, 4000–10,000 IU human chorionic gonadotropin (hCG) was administered when more than 60% of follicles were > 16 mm in diameter. Transvaginal ultrasound-guided oocyte re-trieval was performed 36–37 h after hCG injection, followed by IVF or ICSI based on sperm parameters. Embryos were scored according to the morphology assessment de-scribed by the Istanbul Consensus [24].

Sample collection

Serum samples from the volunteers were collected on two specific occasions: the third day of menstruation before the IVF-ET cycle (referred to as base serum) and on the day of human chorionic gonadotropin (hCG) injection (referred to as hCG day serum). Following blood extraction from the patients’ veins, it underwent centrifugation at 3500 g for 10 min. The resulting supernatant was gathered and stored at -20 °C for subsequent experiments.

The follicular fluid was collected concurrently with oocyte retrieval [25]. Briefly, transvaginal ultrasound-guided oocyte retrieval was conducted 36–37 h following hCG injection, coinciding with the collection of follicular fluid. Subsequently, the gathered follicular fluid underwent centrifugation at 4 °C and 1000 g for 10 min. The resultant supernatant was then collected and stored at -80 °C for subsequent experiments.

Enzyme-Linked Immunosorbent Assay (ELISA)

Melatonin levels were quantified using an MT Enzyme-Linked Immunosorbent Assay (HM10652, Bioswamp, Wuhan, China) following the manufacturer’s guidelines. Initially, 50 µL/well of standard substances at various concentrations (0, 25, 50, 100, 200, and 400 pg/mL) or 40 µL/well of serum and follicular fluid, along with 10 µL/well of bi-otin-labeled anti-melatonin antibody, were added to 96-well plates. Subsequent steps involved adding 50 µL/well of the enzyme label reagent, followed by a 30-minute incu-bation at room temperature. Post-incubation, the plates underwent five washes with a wash buffer and were developed with 100 µL of reagent. The reaction was terminated using a stop solution, and absorbance readings were taken at 450 nm. The concentration of MT in each sample was determined based on standard substance calibration. Each treatment was analyzed in triplicate and repeated independently at least three times.

Statistical analyses

Data analysis was conducted using SPSS (Statistical Package for Social Sciences IBM Corporation, Armonk, NY, USA) version 24.0. Quantitative datas were presented as mean ± standard deviation ± s. Count datas were expressed as percentages (%). For quantitative datas within each group, One-Way ANOVA was applied, followed by pairwise comparisons using Fisher’s Least Significant Difference method for equal vari-ance parameters and Tamhane T2 for unequal variance parameters. The association be-tween melatonin levels and other parameters was explored using the Spearman rank correlation method. Statistical significance was set at P < 0.05 for all tests.

Results

Baseline characteristics of patients with NOR, DOR-Path, and DOR-Phy

Eighty-five patients were recruited for this study and stratified into three groups based on age and ovarian reserve status: two experimental groups (DOR-Path, n = 25 and DOR-Phy, n = 33) and a control group (NOR, n = 27). Detailed baseline characteristics are presented in Table 1. Parameters such as average age, BMI, duration of infertility, serum hormone levels and infertility factors were compared among the groups. The results showed that, as expected, significant differences emerged between the DOR-Path and NOR groups in bFSH, AFC, AMH. However, no significant differences were noted in age, BMI, infertility duration, bLH, bE2, and P. Similarly, comparisons between the DOR-Phy and NOR groups highlighted significant differences in age, bFSH, AFC and AMH. Conversely, BMI, infertility duration, bLH, bE2, and P showed no significant differences. In the comparison between DOR-Path and DOR-Phy groups, significant differences were observed in age, bFSH, and AMH. However, no significant differences were found in BMI, infertility duration, bLH, bE2, P and AFC. The findings illustrate substantial variations in negative predictors (age, bFSH) and positive predictors (AFC, AMH) linked to physiological ovarian reserve hypoplasia in comparison to the NOR group. Likewise, considerable differences in negative predictors (bFSH) and positive predictors (AFC, AMH) were observed concerning pathological ovarian reserve hypoplasia.

Table 1 The baseline characteristics of patients with NOR, DOR-Path and DOR-Phy
Full size table

Melatonin levels in patients with DOR-Path, DOR-Phy and NOR

To comprehensively evaluate melatonin level variations among patients with DOR-Path, DOR-Phy, and NOR, we conducted ELISA assays on samples of patient serum (base serum and hCG day serum) and follicular fluid collected on the day of oocyte retrieval. Figure 1 illustrates the outcomes. Analysis of melatonin levels in base serum re-vealed a significant decrease (P < 0.05) in both the DOR-Path and DOR-Phy groups com-pared to the NOR group. However, no notable difference was observed between the DOR-Path and DOR-Phy groups. The values were 183.26 ± 43.90 (pg/mL) for the NOR group, 149.63 ± 43.78 (pg/mL) for the DOR-Path group, and 149.30 ± 37.88 (pg/mL) for the DOR-Phy group (Fig. 1a). Examination of melatonin levels in hCG day serum indicated no significant differences among patients in the DOR-Path, DOR-Phy, and NOR groups (Fig. 1b). Conversely, the analysis of melatonin levels in follicular fluid showcased the lowest levels in the DOR-Path group and the highest in the NOR group. Significant differences were evident between both the DOR-Path (145.43 ± 39.30 pg/mL) and DOR-Phy groups (162.30 ± 59.66 pg/mL) when compared with the NOR group (236.84 ± 55.26 pg/mL) (P < 0.001) (Fig. 1c).

Subsequently, we conducted an analysis of melatonin levels in volunteers categorized into distinct groups. Comparisons of melatonin levels in serum and follicular fluid at different stages indicated the highest levels in follicular fluid and the lowest in hCG day serum (Fig. 1d–f). Noteworthy differences in melatonin levels were observed within the NOR group: significant disparities between base day serum and follicular fluid (P < 0.001), as well as between hCG day serum and follicular fluid (P < 0.001) (Fig. 1d). However, no significant difference emerged in melatonin levels between serum on the base day and hCG day. The values were 183.26 ± 43.90 (pg/mL) for the base serum, 164.03 ± 55.78 (pg/mL) for the hCG day serum, and 236.84 ± 55.26 (pg/mL) for the follicular fluid (Fig. 1d). In contrast, the melatonin levels within each sample in the DOR-Path and DOR-Phy groups exhibited no significant differences between them (Fig. 1e, f).

These findings indicate distinct melatonin level variations in the base serum and follicular fluid among patients with DOR-Path, DOR-Phy, and NOR. Particularly note-worthy are significantly lower melatonin levels in the DOR-Path and DOR-Phy groups compared to the NOR group in follicular fluid.

Fig. 1
figure 1

Melatonin Levels in NOR Group, DOR-Path Group, and DOR-Phy Group. (a) Compared with the control subjects (n = 27), base serum melatonin levels were reduced in patients with DOR-Path (n = 25) and DOR-Phy (n = 33); (b) There were no significant differences in serum melato-nin concentrations on hCG day among NOR Group, DOR-Path, and DOR-Phy patients; (c) Com-pared with the NOR Group, Melatonin levels in the follicular fluid were reduced in patients with DOR-Path and DOR; (d) The melatonin levels of different specimens in NOR Group; (e) The melatinin levels of different specimens in DOR-Path patients; (f) The melatonin levels of different specimens in elderly DOR-Phy patients; When the P < 0.05, it indicates statistical significance

Full size image

Comparative analysis of IVF outcomes in patients with DOR-Path, DOR-Phy, and NOR

Upon comparing IVF outcomes among the three groups, we noted that patients in the DOR-Path and DOR-Phy cohorts with low melatonin levels experienced inferior IVF outcomes. As illustrated in Table 2, there were significant disparities between the DOR-Path and NOR groups in variables such as the number of oocytes, oocytes/AFC, 2PN embryos, cleavage, day 3 usable embryos, and day 3 good quality embryos (P < 0.001). Similarly, the DOR-Phy group demonstrated comparable outcomes to the NOR group (P < 0.001). However, no statistically significant difference was found between the DOR-Path and DOR-Phy groups.

Table 2 Comparisons of IVF outcomes among patients with NOR, DOR-Path and DOR-Phy
Full size table

Melatonin levels in serum and follicular fluid can predict IVF outcomes

To delve deeper into the predictive role of melatonin in serum and follicular fluid regarding IVF outcomes, we examined the correlation between melatonin levels in serum and follicular fluid and the parameters of IVF outcomes. Our observations revealed a significant positive correlation between melatonin levels in serum and follicular fluid and the parameters of IVF outcomes (Fig. 2). The most robust correlations in follicular fluid melatonin levels with IVF outcome parameters (Fig. 2k-o) include the number of oocytes (rs=0.506, P < 0.001), cleavage (rs=0.552, P < 0.001), 2PN (rs=0.551, P < 0.001), day 3 usable embryos (rs = 0.483, P < 0.001), and day 3 good quality embryos (rs=0.586, P < 0.001). A relatively strong correlation was observed between melatonin levels in base serum and IVF outcome parameters (Fig. 2a-e), including the number of oocytes (rs=0.291, P = 0.007), cleavage (rs=0.338, P = 0.002), 2PN (rs=0.329, P = 0.002), day 3 usable embryos (rs=0.276, P = 0.010), and day 3 good quality embryos (rs=0.356, P = 0.001). Additionally, melatonin levels in hCG day serum exhibited a less pronounced correlation with IVF outcomes, but they remained significantly different (P < 0.05) (Fig. 2f-j), involving the number of oocytes (rs=0.232, P = 0.033), cleavage (rs=0.273, P = 0.012), 2PN (rs=0.258, P = 0.017), day 3 usable embryos (rs=0.241, P = 0.027), and day 3 good quality embryos (rs=0.316, P = 0.003). Based on the aforementioned results, melatonin levels in base serum, hCG day serum, and follicular fluid exhibit a significant positive correlation with IVF outcomes.

Fig. 2
figure 2

Correlation between the melatonin levels in base serum and follicular fluid and IVF out-comes (n = 85). (a-e) Correlation between IVF outcomes and melatonin levels in base Serum; (f-j) Correlation between IVF outcomes and melatonin levels in hCG Day Serum; (k-o) Correlation between IVF outcomes and melatonin levels in follicular fluid; When the P < 0.05, it indicates statistical significance

Full size image

Discussion

In this study, we measured melatonin levels in basal serum, hCG day serum, and follicular fluid among patients with DOR-Path, DOR-Phy, and NOR. The results indicated that, in comparison with the NOR group, the DOR group exhibited significantly lower levels of melatonin in both basal serum and follicular fluid (Table S1). Subsequently, the study analyzed the correlation between these melatonin levels and clinical parameters as well as IVF outcomes. It was discovered that melatonin levels in serum and follicular fluid were strongly associated with age, bFSH, AFC, and AMH—established predictors of ovarian reserve. Furthermore, melatonin levels played a pivotal role in IVF outcomes; patients with higher melatonin levels retrieved more oocytes. The number of 2PN, cleaved zygotes, available embryos on day 3, and good-quality embryos on day 3 significantly increased with melatonin levels from the DOR group to the NOR group. Consequently, melatonin levels in serum and follicular fluid may serve as reliable predictors of ovarian reserve and IVF outcomes.

Research has demonstrated significantly higher levels of ROS in the follicular fluid of patients with DOR compared to relatively healthy women. Excessive ROS further compromises oocyte quality by disrupting the follicular microenvironment [26]. Despite the critical role of ROS in cellular signal transduction and internal equilibrium, an excess of ROS can induce changes in genetic material, signaling pathways, transcription factors, and the ovarian microenvironment. This process accelerates the aging of oocytes and ovarian granulosa cells [7]. Melatonin, functioning as a broad-spectrum antioxidant and a potent free radical scavenger, can collaboratively counteract excessive intracellular ROS by initiating a cascade reaction and regulating the transcription of antioxidant enzyme genes [11, 27]. Evidence suggests that melatonin enhances ovarian function in infertile patients through various roles, including antioxidant, anti-apoptotic, and endocrine modulation [14, 28].

Consistent with the research findings of Tamura et al. [15], the concentration of melatonin in the follicular fluid of relatively healthy women is higher than that in their peripheral blood. This occurrence might be attributed to the capability of granulosa cells and oocytes in follicles to absorb melatonin from peripheral blood [29]. Therefore, we posit that melatonin, acting as the primary antioxidant in follicular fluid, could shield oocytes from oxidative damage by neutralizing ROS, thereby positively in-fluencing oocyte quality. Nevertheless, in the DOR-Path and DOR-Phy groups, melatonin concentrations in peripheral blood (basal serum, hCG day serum) and follicular fluid were lower than those in the NOR group. Notably, there were no significant differences in melatonin concentrations in peripheral blood and follicular fluid between the DOR-Path and DOR-Phy groups. Consequently, the elevated ROS in the follicle induced by age or pathological conditions cannot be offset by high melatonin concentrations, ultimately impacting oocyte quality [4, 30, 31].

As widely recognized, the quality of oocytes plays a pivotal role in influencing IVF outcomes. In this study, we observed a positive correlation between melatonin levels in base serum, hCG day, and follicular fluid, and IVF outcomes. Individuals with elevated melatonin levels exhibit heightened production of oocytes, 2PN-fertilized oocytes, zygotes cleaved, and D3 good-quality embryos. Importantly, this correlation experiences a substantial increase from the DOR group to the NOR group. This finding aligns with the results reported in the study conducted by Tong et al. on melatonin levels in follicular fluid [19].

When analyzing the correlation between melatonin levels and patients’ clinical characteristics, a good correlation emerged between melatonin levels in both serum and follicular fluid and current clinical indicators of ovarian reserve function, including age, bFSH, AFC, and AMH. The amount of melatonin produced by human pineal gland di-minishes with advancing age [32]. Melatonin production by the human pineal gland di-minishes with age. Several studies suggest that this decline may be attributed to increased calcium deposition in the pineal gland, a reduction in pineal N-acetyltransferase, or a gradual alteration in the concentration of melatonin α1 receptors in the hypothalamus [33,34,35]. According to our findings, this age-related decline in melatonin, the same trend was found in serum and follicular fluid from the NOR group to the DOR-phy group. In mouse experiments, melatonin deficiency intensifies follicle activation and atresia, hastening the age-related decline in fertility. Conversely, the presence of melatonin in the body hinders follicle activation, growth, and atresia via the PI3K-AKT pathway, consequently retarding ovarian aging [36]. Additionally, our findings revealed a negative correlation between melatonin levels in serum and follicular fluid and bFSH levels, aligning with prior research [18, 37]. Moreover, our results demonstrated a significant and positive correlation between melatonin levels in both serum and follicular fluid with AFC and AMH, in agreement with the findings reported by Min et al. [38]. Hence, melatonin levels in both serum and follicular fluid emerge as biochemical markers strongly correlated with age, bFSH, AFC, AMH, oocyte number, and embryo quality. These markers exhibit promising potential as excellent predictive factors for both ovarian reserve and IVF outcomes.

In contrast to alternative markers of ovarian reserve, melatonin is a stable endoge-nously produced compound that can also be acquired through in vitro uptake. Research indicates that melatonin plays a pivotal role in mitigating oxidative stress and preventing oocyte apoptosis, while concurrently enhancing mitochondrial function. These effects contribute to the improvement of oocyte quality and enhance pregnancy outcomes in infertile patients [39,40,41]. In a study conducted by Song et al., ovarian senescence was significantly reduced in mice following the administration of melatonin for 6–12 months. This was substantiated by melatonin’s ability to inhibit age-related declines in follicle number, litter size, and blastocyst rate [42]. Moreover, Bao et al. demonstrated that the addition of melatonin to the culture medium increased the percentage of high-quality Day 3 embryos in patients with recurrently poor-quality embryos. Additionally, it enhanced the blastocyst rate of vitrified-thawed cleavage embryos [43]. Therefore, the efficacy of melatonin supplementation in both embryo cultures and oocyte maturation medium for enhancing embryo quality in patients with DOR could be substantiated through additional clinical trials.

In addition, it is crucial to acknowledge the limitations of our study. Notably, we refrained from analyzing the implantation and pregnancy rates. This decision was in-fluenced by the cancellation of fresh embryo transfers in certain patients with DOR due to factors such as thin endometrium or inadequate embryo availability.

Conclusions

In conclusion, our study demonstrates that melatonin in serum and follicular fluid, as a highly correlated indicator of ovarian reserve, oocyte number, and embryo quality, has great potential to be a predictive marker of ovarian reserve and IVF outcome. However, further large-scale prospective studies are needed to validate our results.

Data availability

The data presented in this study are available in the article.

Change history

References

  1. Zhou G, Gu Y, Zhou F, et al. The emerging roles and therapeutic potential of Extracellular vesicles in infertility. Front Endocrinol (Lausanne). 2021;12:758206.

    PubMed  Google Scholar 

  2. Carson SA, Kallen AN. Diagnosis and management of infertility: a review. JAMA. 2021;326(1):65–76.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Direkvand-Moghadam A, Delpisheh A, Sayehmiri K. An investigation of the worldwide prevalence of infertility as a systematic review. Qom Univ Med Sci. 2016;10(1):76–87.

    Google Scholar 

  4. Reiter RJ, Sharma R, Romero A, et al. Aging-related ovarian failure and infertility: melatonin to the rescue. Antioxid (Basel). 2023;12(3):695.

    CAS  Google Scholar 

  5. Devine K, Mumford SL, Wu M, et al. Diminished ovarian reserve in the United States assisted reproductive technology pop-ulation: diagnostic trends among 181,536 cycles from the Society for Assisted Reproductive Technology Clinic outcomes Reporting System. Fertil Steril. 2015;104(3):612–e193.

    PubMed  PubMed Central  Google Scholar 

  6. Yan F, Zhao Q, Li Y, et al. The role of oxidative stress in ovarian aging: a review. J Ovarian Res. 2022;15(1):100.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Shi YQ, Zhu XT, Zhang SN, et al. Premature ovarian insufficiency: a review on the role of oxidative stress and the application of antioxidants. Front Endocrinol (Lausanne). 2023;14:1172481.

    PubMed  Google Scholar 

  8. Tamura H, Jozaki M, Tanabe M, et al. Importance of melatonin in assisted Reproductive Technology and ovarian aging. Int J Mol Sci. 2020;21(3):1135.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Zhang Y, Liu T, Yang H, et al. Melatonin: a novel candidate for the treatment of osteoarthritis. Ageing Res Rev. 2022;78:101635.

    CAS  PubMed  Google Scholar 

  10. Zhao D, Yu Y, Shen Y, et al. Melatonin synthesis and function: evolutionary history in animals and plants. Front Endocrinol (Lausanne). 2019;10:249.

    PubMed  Google Scholar 

  11. Reiter RJ, Mayo JC, Tan DX, et al. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61(3):253–78.

    CAS  PubMed  Google Scholar 

  12. Chitimus DM, Popescu MR, Voiculescu SE, et al. Melatonin’s impact on antioxidative and anti-inflammatory Reprogram-Ming in Homeostasis and Disease. Biomolecules. 2020;10(9):1211.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Minich DM, Henning M, Darley C, et al. Is melatonin the next vitamin D? A review of emerging Science, Clinical uses, Safety, and Dietary supplements. Nutrients. 2022;14(19):3934.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Guo YM, Sun TC, Wang HP, et al. Research progress of melatonin (MT) in improving ovarian function: a review of the current status. Aging. 2021;13(13):17930–47.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Tamura H, Takasaki A, Taketani T, et al. The role of melatonin as an antioxidant in the follicle. J Ovarian Res. 2012;5:5.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Lohrasbi P, Karbalay-Doust S, Mohammad Bagher Tabei S, et al. The effects of melatonin and metformin on histological characteristics of the ovary and uterus in letrozole-induced polycystic ovarian syndrome mice: a stereological study. Int J Reprod Biomed. 2022;20(11):973–88.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Feng J, Ma WW, Li HX, et al. Melatonin prevents cyclophosphamide-induced primordial follicle loss by inhibiting ovarian granulosa cell apoptosis and maintaining AMH expression. Front Endocrinol (Lausanne). 2022;13:895095.

    PubMed  Google Scholar 

  18. Dumesic DA, Meldrum DR, Katz-Jaffe MG, et al. Oocyte environment: follicular fluid and cumulus cells are critical for oocyte health. Fertil Steril. 2015;103(2):303–16.

    PubMed  Google Scholar 

  19. Tong J, Sheng S, Sun Y, et al. Melatonin levels in follicular fluid as markers for IVF outcomes and predicting ovarian reserve. Reproduction. 2017;153(4):443–51.

    CAS  PubMed  Google Scholar 

  20. Expert group of consensus on clinical diagnosis &. Management of diminished ovarian reserve; Reproductive endocrinology & fertility preservation section of Chinese society on fertility preservation under Chinese preventive medicine association.Consensus on clinical diagnosis and management of diminished ovarian reserve. J Reprod Med. 2022;31(04):425–34.

    Google Scholar 

  21. Zhao D, Xie R, Li X. Comparison of pregnancy outcome after fresh embryo transfer between GnRH antagonist and GnRH agonist regimens in patients with thin endometrium. Front Med (Lausanne). 2023;10:1071014.

    PubMed  Google Scholar 

  22. Datta AK, Maheshwari A, Felix N, et al. Mild versus conventional ovarian stimulation for IVF in poor, normal and hy-per-responders: a systematic review and meta-analysis. Hum Reprod Update. 2021;27(2):229–53.

    CAS  PubMed  Google Scholar 

  23. Lu BJ, Lin CJ, Lin BZ, et al. ART outcomes following ovarian stimulation in the luteal phase:a systematic review and me-ta-analysis. J Assist Reprod Genet. 2021;38(8):1927–38.

    PubMed  PubMed Central  Google Scholar 

  24. Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus work-shop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011;26(6):1270–83.

    Google Scholar 

  25. Rostami S, Alyasin A, Saedi M, et al. Astaxanthin ameliorates inflammation, oxidative stress, and reproductive outcomes in endometriosis patients undergoing assisted reproduction: a randomized, triple-blind placebo-controlled clinical trial. Front Endocrinol (Lausanne). 2023;14:1144323.

    PubMed  Google Scholar 

  26. Zhao N, Zhang C, Wu Y, et al. ROS-CCL5 axis recruits CD8 + T lymphocytes promoting the apoptosis of granulosa cells in diminished ovary reserve. J Reprod Immunol. 2023;155:103789.

    CAS  PubMed  Google Scholar 

  27. Kryl’skii ED, Popova TN, Safonova OA, et al. Transcriptional regulation of antioxidant enzymes activity and modulation of oxidative stress by melatonin in rats under cerebral ischemia / reperfusion conditions. Neuroscience. 2019;406:653–66.

    PubMed  Google Scholar 

  28. Tamura H, Kawamoto M, Sato S, et al. Long-term melatonin treatment delays ovarian aging. J Pineal Res. 2017;62(2). https://doiorg.publicaciones.saludcastillayleon.es/10.1111/jpi.12381.

  29. Reiter RJ, Tamura H, Tan DX, et al. Melatonin and the circadian system: contributions to successful female reproduction. Fertil Steril. 2014;102(2):321–8.

    CAS  PubMed  Google Scholar 

  30. Huang Y, Cheng Y, Zhang M, et al. Oxidative stress and inflammatory markers in ovarian follicular fluid of women with diminished ovarian reserve during in vitro fertilization. J Ovarian Res. 2023;16(1):206.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Duan H, Hu J, Xiao L, et al. β-Estradiol inhibits melatonin synthesis and melatonin receptor expression in sheep granulosa cells. Gene. 2022;814:146128.

    CAS  PubMed  Google Scholar 

  32. Espino J, Pariente JA, Rodríguez AB. Oxidative stress and immunosenescence: therapeutic effects of melatonin. Oxid Med Cell Longev. 2012;2012:670294.

    PubMed  PubMed Central  Google Scholar 

  33. Tan DX, Xu B, Zhou X, et al. Pineal calcification, Melatonin Production, Aging, Associated Health Consequences and Reju-Venation of the pineal gland. Molecules. 2018;23(2):301.

    PubMed  PubMed Central  Google Scholar 

  34. Klein DC, Coon SL, Roseboom PH, et al. The melatonin rhythm-generating enzyme: molecular regulation of serotonin N-acetyltransferase in the pineal gland. Recent Prog Horm Res. 1997;52:307–58.

    CAS  PubMed  Google Scholar 

  35. Cardinali DP, Vacas MI. Cellular and molecular mechanisms controlling melatonin release by mammalian pineal glands. Cell Mol Neurobiol. 1987;7(4):323–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Petterborg LJ, Richardson BA, Vaughan MK, et al. Acute effects of a single afternoon melatonin injection on LH, prolactin, and pineal melatonin titers in the Syrian hamster. J Neural Transm. 1984;59(4):299–307.

    CAS  PubMed  Google Scholar 

  37. Walecka-Kapica E, Chojnacki J, Stępień A, et al. Melatonin and female hormone secretion in postmenopausal overweight women. Int J Mol Sci. 2015;16(1):1030–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Zheng M, Tong J, Li WP, et al. Melatonin concentration in follicular fluid is correlated with antral follicle count (AFC) and in vitro fertilization (IVF) outcomes in women undergoing assisted reproductive technology (ART) procedures. Gynecol Endocrinol. 2018;34(5):446–50.

    CAS  PubMed  Google Scholar 

  39. Cruz MH, Leal CL, da Cruz JF, et al. Role of melatonin on production and preservation of gametes and embryos: a brief review. Anim Reprod Sci. 2014;145(3–4):150–60.

    CAS  PubMed  Google Scholar 

  40. Showell MG, Mackenzie-Proctor R, Jordan V, et al. Antioxidants for female subfertility. Cochrane Database Syst Rev. 2020;8(8):CD007807.

    PubMed  Google Scholar 

  41. Hu KL, Ye X, Wang S, et al. Melatonin application in assisted Reproductive Technology: a systematic Review and Me-ta-Analysis of Randomized trials. Front Endocrinol (Lausanne). 2020;11:160.

    PubMed  Google Scholar 

  42. Song C, Peng W, Yin S, et al. Melatonin improves age-induced fertility decline and attenuates ovarian mitochondrial oxidative stress in mice. Sci Rep. 2016;6:35165.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Bao Z, Li G, Wang R, et al. Melatonin improves quality of repeated-poor and frozen-thawed embryos in Human, a prospective clinical trial. Front Endocrinol (Lausanne). 2022;13:853999.

    PubMed  Google Scholar 

Download references

Acknowledgements

We thank the study staff and all the patients who participated in this study.

Funding

Shenzhen Key Medical Discipline Construction Fund (grant number SZXK054).

Author information

Author notes

  1. Yingying Wang and Shangjie Liu contributed equally to this work.

Authors and Affiliations

  1. School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, 453003, China

    Yingying Wang, Xiuming Zhang & Zhou Zheng

  2. Department of Medical Laboratory and Reproductive Medicine, The Third Affiliated Hospital of Shenzhen University, Shenzhen, 518000, China

    Yingying Wang, Shangjie Liu, Feifei Gan, Dan Xiong, Xiuming Zhang & Zhou Zheng

Authors
  1. Yingying Wang
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Shangjie Liu
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Feifei Gan
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Dan Xiong
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Xiuming Zhang
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Zhou Zheng
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

Z.Z and S.J.L conceived and designed the study; Z.Z and X.M.Z acquired funding; Y.Y.W and Z.Z performed the analysis; D.X and F.F.G contributed analytic tools; D.X and S.J.L supervised the work; Y.Y.W and Z.Z wrote the original draft, reviewed and edited the paper. All authors have read and agreed to the published version of the manuscript.

Corresponding authors

Correspondence to Xiuming Zhang or Zhou Zheng.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Research Ethics Commit-tee of the Luohu District People’s Hospital (2023-LHQRMYY-KYLL-044). Ethical issues regarding plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, and redundancy have been completely observed by the author. Informed consent was obtained from all subjects involved in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article has been retracted. Please see the retraction notice for more detail: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12958-025-01382-3

Electronic supplementary material

Below is the link to the electronic supplementary material.

12958_2024_1296_MOESM1_ESM.docx

Supplementary Materials 1: Table S1: Correlation between the melatonin levels in base serum and follicular fluid and BMI, bLH, bE2 and P levels (n = 85)

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Y., Liu, S., Gan, F. et al. RETRACTED ARTICLE: Melatonin levels and embryo quality in IVF patients with diminished ovarian reserve: a comparative study. Reprod Biol Endocrinol 22, 127 (2024). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12958-024-01296-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12958-024-01296-6

Keywords

Reproductive Biology and Endocrinology

ISSN: 1477-7827

Contact us